Johnson & Johnson takes rare gamble on microbiome science of biotech startup
Second Genome has raised the profile of its early drug research in an emerging area of microbial science, inking a collaboration deal with a pharma unit of industry giant Johnson & Johnson. Janssen Biotech, the J&J unit, and the San Bruno, Calif.-based startup have joined forces on microbiome drug discovery in hopes of finding new treatments for the inflammatory bowel disease known as ulcerative colitis.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063